CHPA workshops
This article was originally published in The Tan Sheet
Executive Summary
FDA and CHPA will co-sponsor a cGMP workshop on drug quality issues. Sessions include Office of Compliance Director David Horowitz on "Current Topics and Progress on the risk based Approach" and FDA district directors on 483 compliance trends. Three separate workshops will be held in Parsippany, N.J. June 6, Chicago July 14 and Santa Monica Aug. 4. Participants can register through the CHPA 1website...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.